Summary of main targeted drugs for breast cancer in the market

Drug name

Indication

Target/Pathway

Developed by

Approval date

Marketing region

Talzenna (talazoparib)

Locally advanced or metastatic breast cancer

PARP-2, PARP1

Pfizer

Oct. 2018

U.S.

Trastuzumab-dkst (Ogivri)

HER2-overexpressing breast cancer

HER2

Mylan/Biocon

Dec. 2017

U.S.

Abemaciclib (VERZENIO)

HR+, HER2- advanced or recurrent breast cancer

CDK 4/6

Eli Lilly

Sep. 2017

U.S.

Neratinib (Nerlynx)

Early-stage, HER2-postive breast cancer

EGFR, HER1, HER2, HER4

Puma Biotech

July 2017

U.S.

Ribociclib (Kisqali)

HR+/HER2- locally advanced or metastatic breast cancer

CDK 4/6

Novartis

Mar. 2017

U.S.

Palbociclib (Ibrance)

Metastatic breast cancer, HR+/HER2- advanced or metastatic breast cancer

CDK4/6

Pfizer

Feb. 2015

U.S.

Lynparza (olaparib)

BRCA-mutated ovarian cancer, BRCA-mutated HER2-negative metastatic breast cancer previously treated with chemotherapy or endocrine therapy

PARP

AstraZeneca

Dec. 2014

EU

Kadcyla (ado-trastuzumab emtansine)

HER2+ advanced (metastatic) breast cancer

Tubulin, HER2

Roche Genentech

Feb. 2013

U.S.

Pertuzumab (Perjeta)

People who have HER2-positive metastatic breast cancer and who have not received anti-HER2 therapy or chemotherapy

HER2/HER3

Roche Genentech

June 2012

U.S.

EdbulinMesylate (Halaven)

Metastatic breast cancer

Tubulin

Eisai

Nov. 2010

U.S.

Ixempra (Ixabepilone)

Advanced breast cancer

Tubulin

Squibb

Oct. 2007

U.S.

lapatinib (Tykerb)

Advanced or metastatic breast cancer

HER2, EGFR

GSK

Mar. 2007

U.S.

 toremifene (Fareston)

Metastatic breast cancer

SERMS

Orion Corporation

2005

U.S.

Bevacizumab/Avastin

Her2- metastatic breast cancer

VEGF-A

Genentech

Feb. 2004

U.S.

Faslodex(fulvestrant,

ER+ metastatic breast cancer

ERS

AstraZeneca

Apr. 2002

U.S.

 Everolimus (Afinitor）

Advanced breast cancer

mTOR

Novartis

July 2003

Sweden

Trastuzumab (Herceptin)

HER2-overexpressing breast cancer

HER2

Genentech

Sep. 1998

U.S.

exemestane (Aromasin)

Metastatic breast cancer and early-stage breast cancer

Aromatase inhibitor

Pfizer

Oct. 1997

U.S.

letrozole (Femara®)

Hormone-receptor-positive, early-stage breast cancer

Aromatase inhibitor

Novartis

July 1996

Sweden

anastrozole (Arimidex)

Advanced breast cancer

Aromatase inhibitor

AstraZeneca

1995

U.S.

tamoxifen (Nolvadex)

Hormone-receptor-positive breast cancer

SERMS

AstraZeneca

1977

U.S.